Navigation Links
Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions
Date:5/8/2008

3 countries. FLECTOR(R) Patch has been used in more than six million patients with a total of approximately 175 million patches dispensed.

Important Safety Information

Cardiovascular risk

-- NSAIDs may cause an increased risk of serious cardiovascular thrombotic

events, myocardial infarction, and stroke, which can be fatal. This

risk may increase with duration of use. Patients with cardiovascular

disease or risk factors for cardiovascular disease may be at greater

risk.

-- FLECTOR(R) Patch is contraindicated for the treatment of peri-operative

pain in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal risk

-- NSAIDs cause an increased risk of serious gastrointestinal adverse

events including bleeding, ulceration, and perforation of the stomach

or intestines, which can be fatal. These events can occur at any time

during use and without warning symptoms. Elderly patients are at

greater risk for serious gastrointestinal events.

Carefully consider the potential benefits and risks of FLECTOR(R) Patch and other treatment options before deciding to use FLECTOR(R) Patch.

FLECTOR(R) Patch is contraindicated in patients with known hypersensitivity to diclofenac. FLECTOR(R) Patch should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

FLECTOR(R) Patch should not be applied to non-intact or damaged skin resulting from any etiology, eg, exudative dermatitis, eczema, infected lesion, burns or wounds.

NSAIDs, including FLECTOR(R) Patch, can cause serious skin adverse events such as exfoliative dermatitis, Stevens
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
3. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... July 11, 2014  Veran Medical Technologies, ... today the positive, cost-effective final results for ... procedure. The SPiNPerc endobronchial percutaneous biopsy study ... approach to biopsy when a traditional bronchoscopic ... physicians experience positive financial outcomes when more ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
(Date:7/12/2014)... July 12, 2014 As reported in ... of Standards and Technology), the June 25th, 2014 Supreme Court ... discovery world. It was also met with both ... on whether it was seen from an individual privacy perspective, ... is fact, there is now precedent which will require law ...
(Date:7/12/2014)... July 12, 2014 A recent article released ... a trio of suggestions for those seeking cosmetic surgical ... are rapidly approaching and the heat begins to enliven the ... their summer clothing, realizing that they didn’t work out as ... This can cause a sudden surge of people eager to ...
(Date:7/12/2014)... Seattle, Wa (PRWEB) July 12, 2014 ... by Doctors Sen and Samantha Pearson, a couple boasting ... chose to launch Restore My Vision Today as a ... that many ophthalmologists have become in their respective ... makes readers privy to a “secret” trove of pertinent ...
(Date:7/12/2014)... 2014 The largest pure occupational medicine ... to announce that it will be opening its fifth ... will join four Atlanta-based Nova Medical Centers’ locations. The ... Deans Bridge Road, and will be open from 8:30 ... “With Nova’s treatment philosophy of rapid return-to-work and decreased ...
(Date:7/11/2014)... DressyQuinceanera.com, a well-known wedding dress manufacturer and retailer, has ... online category. Furthermore, the firm has announced that all ... to 62% off. , The brand new Quinceanera Dama ... quality and style. All items in the new collection ... the company’s other items: lace evening dresses, short bridesmaid ...
Breaking Medicine News(10 mins):Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2
... (January 25, 2008) Research in the January issue ... (JACS) shows that many patients with minimal injuries ... and II trauma centers, despite the ability of the ... that overuse of trauma centers threatens to limit the ...
... Inc. (NYSE: WTW ) announced today that ... Sardini, Chief Financial,Officer, will present at the Credit ... The presentation will be held on Tuesday, ... a.m. local time) and will be accessible via ...
... to encourage Americans to ... 25 , Who: "The Biggest Loser" Season Four winner Bill Germanakos ... with MSN Health & Fitness and ... discuss "The Biggest Loser" Million Pound Match-Up sweepstakes, at ...
... Doctors Care is,pleased to announce the opening of its ... Hoffmeyer Road, Florence. The new center opened,January 23, 2008. ... scheduled to,open soon., Dr. Thomas Gibbons, the Midlands ... "Doctors Care is excited to provide convenient,urgent care, family ...
... 300-bed facility in Tempe, Arizona, raises MDS capacity in the ... Phoenix-area to 420 ... MDS Pharma,Services (http://www.mdsps.com ), a leading provider of innovative drug ... a new 300-bed Phase I facility in nearby Tempe, Arizona. The ...
... Md., Jan. 25 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... commercializing novel anti-infective products, today,announced that it has ... the private placement of 8,750,000 shares of,its common ... includes,five-year warrants to purchase 3,500,000 shares of common ...
Cached Medicine News:Health News:Excessive overtriage in US trauma centers overwhelming system resources, delaying patient care 2Health News:Weight Watchers to Present at Credit Suisse 10th Annual Global Services Conference 2Health News:Bill Germanakos and Hollie Self Bring 'The Biggest Loser' Million-Pound Tour, Presented by MSN, to Arizona Mills Mall 2Health News:UCI Medical Affiliates Inc. Opens New Doctors Care Center in Florence 2Health News:MDS Pharma Services Opens Largest Phase I Clinic on U.S. West Coast 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 3Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: